Clinical Trial Update: A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

This update reports on a completed Phase II trial of MGCD0103 (mocetinostat) in patients with refractory Chronic Lymphocytic Leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• MGCD0103 (mocetinostat)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Lymphocytic Leukemia, Chronic | Phase 2 | Status: COMPLETED